Benefits
Body fat reduction
A meta-analysis of 18 RCTs confirms CLA supplementation produces a modest but statistically significant reduction in body fat mass (approximately 0.05 kg/week or ~0.7 kg over 12 weeks). The t10,c12 isomer specifically reduces adipocyte size and fat storage by inhibiting lipoprotein lipase and increasing fat oxidation in muscle tissue.
Lean body mass preservation
CLA simultaneously reduces fat mass while preserving or slightly increasing lean body mass — producing favorable changes in body composition without caloric restriction. The c9,t11 isomer supports muscle protein synthesis via PPAR-γ modulation, contributing to the lean mass-preserving effect observed in clinical trials.
Immune system modulation
The c9,t11 CLA isomer demonstrates immunomodulatory effects — enhancing NK cell activity, reducing inflammatory cytokine production, and modulating Th1/Th2 immune balance. These immune effects are independent of the body composition mechanisms and have been studied in cancer prevention contexts.
Blood sugar and insulin sensitivity
CLA supplementation modestly improves insulin sensitivity and reduces fasting glucose in some populations, particularly when combined with exercise. The PPAR-γ activation mechanism improves adipocyte insulin signaling and glucose uptake — though effects are inconsistent across studies and populations.
Mechanism of action
Lipoprotein lipase inhibition and adipocyte apoptosis
The t10,c12 CLA isomer inhibits lipoprotein lipase (LPL) in adipose tissue — reducing fatty acid uptake into fat cells — while simultaneously inducing apoptosis (programmed death) of differentiated adipocytes. This dual mechanism reduces both fat storage efficiency and existing adipocyte number, contributing to fat mass reduction over time.
PPAR-α activation and fat oxidation enhancement
CLA isomers activate peroxisome proliferator-activated receptor alpha (PPAR-α) in muscle and liver tissue, upregulating genes for fatty acid oxidation (CPT-1, MCAD, acyl-CoA oxidase). Increased fat oxidation rates shift substrate utilization toward fat, reducing fat accumulation while sparing muscle glycogen.
Stearoyl-CoA desaturase (SCD-1) inhibition
The t10,c12 isomer specifically inhibits stearoyl-CoA desaturase 1 (SCD-1) — a key lipogenic enzyme that converts saturated fatty acids to monounsaturated forms required for fat storage. SCD-1 inhibition reduces the efficiency of fat synthesis and storage in adipose tissue.
Clinical trials
Evidence review and pooled analysis of 18 randomized, placebo-controlled trials examining CLA supplementation (typically 3.2-6.4 g/day, mixed t10,c12 and c9,t11 isomers) on body fat mass and lean body mass. (Am J Clin Nutr)
Pooled across 18 clinical trials.
CLA produced statistically significant but clinically MODEST reduction in body fat mass (-0.05 kg/week; ~0.7 kg over 12 weeks). Effects plateau after ~6 months. Note: effects are small in absolute terms — CLA is NOT a meaningful weight loss intervention. Some safety concerns: t10,c12 isomer associated with insulin resistance, hepatic steatosis, and lipid profile changes (increased Lp(a)) in some trials. Overall risk-benefit favors caution.
Randomized, double-blind, placebo-controlled trial of Tonalin® CLA (3.4 g/day, 50:50 t10,c12 / c9,t11 isomers) vs olive oil placebo in 60 overweight adults for 12 weeks. (J Nutr)
60 overweight or obese adults (BMI 25–35). Randomized double-blind, 5 groups: placebo (9 g olive oil) or 1.7, 3.4, 5.1, or 6.8 g CLA per day × 12 weeks. 47 completed.
CLA at 3.4 g/day and 6.8 g/day produced statistically significant reductions in body fat mass (DXA) vs placebo. No clear dose-response above 3.4 g/day. Lean body mass not adversely affected. Foundational dose-response trial supporting 3.4 g/day as effective dose; this was a key early Tonalin®-era CLA study.